Characterization of binding kinetics and intracellular signaling of new psychoactive substances targeting cannabinoid receptor using transition-based reweighting method
eLife · 2025
DOI: 10.7554/elife.98798 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2025. Verfasst von Soumajit Dutta und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Biomolecular Engineering, University of Illinois at Urbana-Champaign, Urbana, United States. Hauptthemen laut MEDLINE: Psychotropic Drugs, Receptor, Cannabinoid, CB1, Illicit Drugs. Die Arbeit nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Science Foundation, National Institute of General Medical Sciences.
Abstract (Originalsprache)
New psychoactive substances (NPS) targeting human cannabinoid receptor 1 pose a significant threat to society as recreational abusive drugs that have pronounced physiological side effects. These greater adverse effects compared to classical cannabinoids have been linked to the higher downstream β -arrestin signaling. Thus, understanding the mechanism of differential signaling will reveal an important structure-activity relationship essential for identifying and potentially regulating NPS molecules. In this study, we simulate the slow (un)binding process of NPS MDMB-Fubinaca and classical cannabinoid HU-210 from CB 1 using multi-ensemble simulation to decipher the effects of ligand binding dynamics on downstream signaling. The transition-based reweighing method is used for the estimation of transition rates and underlying thermodynamics of (un)binding processes of ligands with nanomolar affinities. Our analyses reveal major interaction differences with transmembrane TM7 between NPS and classical cannabinoids. A variational autoencoder-based approach, neural relational inference (NRI), is applied to assess the allosteric effects on intracellular regions attributable to variations in binding pocket interactions. NRI analysis indicates a heightened level of allosteric control of NPxxY motif for NPS-bound receptors, which contributes to the higher probability of formation of a crucial triad interaction (Y 7.53 -Y 5.58 -T 3.46 ) necessary for stronger β -arrestin signaling. Hence, in this work, MD simulation, data-driven statistical methods, and deep learning point out the structural basis for the heightened physiological side effects associated with NPS, contributing to efforts aimed at mitigating their public health impact.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemical and Biomolecular Engineering, University of Illinois at Urbana-Champaign, Urbana, United States.
- Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, United States.
- Center for Biophysics and Quantitative Biology, University of Illinois at Urbana-Champaign, Urbana, United States.
- Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, United States.
- Cancer Center at Illinois, University of Illinois at Urbana-Champaign, Urbana, United States.
ORCID-Profile: Soumajit Dutta, Diwakar Shukla
Förderung
- NIGMS NIH HHS
- National Science Foundation
- National Institute of General Medical Sciences
Zitieren
APA
Dutta, S., & Shukla, D. (2025). Characterization of binding kinetics and intracellular signaling of new psychoactive substances targeting cannabinoid receptor using transition-based reweighting method. eLife. https://doi.org/10.7554/elife.98798
Vancouver
Dutta S, Shukla D. Characterization of binding kinetics and intracellular signaling of new psychoactive substances targeting cannabinoid receptor using transition-based reweighting method. eLife. 2025. doi:10.7554/elife.98798
BibTeX
@article{Dutta2025,
author = {Dutta, Soumajit and Shukla, Diwakar},
title = {Characterization of binding kinetics and intracellular signaling of new psychoactive substances targeting cannabinoid receptor using transition-based reweighting method},
journal = {eLife},
year = {2025},
doi = {10.7554/elife.98798}
}
EUVIMED